Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?

authors:

avatar Giovanni Tarantino 1 , *

Department of Clinical and Experimental Medicine, School of Naples, Federico II University Medical, Naples, Italy

how to cite: Tarantino G. Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?. Hepat Mon. 2013;13(2):e7560. https://doi.org/10.5812/hepatmon.7560.

References

  • 1.

    Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011;364(25):2392-404. [PubMed ID: 21696306]. https://doi.org/10.1056/NEJMoa1014296.

  • 2.

    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209-18. [PubMed ID: 15690074]. https://doi.org/10.1172/JCI24282.

  • 3.

    Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969-74. [PubMed ID: 20581244]. https://doi.org/10.1136/gut.2009.205088.

  • 4.

    Bosserhoff A, Hellerbrand C. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis. Dig Dis. 2011;29(4):377-83. [PubMed ID: 21894008]. https://doi.org/10.1159/000329800.

  • 5.

    Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008;6:72. [PubMed ID: 19038040]. https://doi.org/10.1186/1479-5876-6-72.

  • 6.

    Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346(8981):987-90. [PubMed ID: 7475591].

  • 7.

    Tarantino G. Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? World J Gastroenterol. 2007;13(35):4669-72. [PubMed ID: 17729388].

  • 8.

    Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M, et al. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond). 2009;6:6. [PubMed ID: 19291292]. https://doi.org/10.1186/1476-9255-6-6.

  • 9.

    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297-307. [PubMed ID: 17135584]. https://doi.org/10.1056/NEJMoa060326.

  • 10.

    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-85. [PubMed ID: 20427778]. https://doi.org/10.1056/NEJMoa0907929.

  • 11.

    Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659-68. [PubMed ID: 21521847]. https://doi.org/10.1001/jama.2011.520.

  • 12.

    Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66-75. [PubMed ID: 22050199]. https://doi.org/10.1111/j.1365-2036.2011.04912.x.

  • 13.

    Birerdinc A, Stepanova M, Pawloski L, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35(1):76-82. [PubMed ID: 22059453]. https://doi.org/10.1111/j.1365-2036.2011.04916.x.

  • 14.

    Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810-20. [PubMed ID: 21319198]. https://doi.org/10.1002/hep.24127.

  • 15.

    Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther. 2011;34(2):214-8. [PubMed ID: 21585409]. https://doi.org/10.1111/j.1365-2036.2011.04695.x.

  • 16.

    Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874-82. [PubMed ID: 21360720]. https://doi.org/10.1002/hep.24268.

  • 17.

    Lee KH, Park SH, Kim YJ, Huh KR, Min KS, Jun SY, et al. [Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors]. Korean J Hepatol. 2010;16(1):29-37. [PubMed ID: 20375640]. https://doi.org/10.3350/kjhep.2010.16.1.29.

  • 18.

    Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011;45(1):55-8. [PubMed ID: 20505526]. https://doi.org/10.1097/MCG.0b013e3181dd1348.

  • 19.

    Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, Morra R, et al. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One. 2008;3(12). e3857. [PubMed ID: 19052646]. https://doi.org/10.1371/journal.pone.0003857.

  • 20.

    Mori M, Fujii H, Ogawa T, Kobayashi S, Iwai S, Morikawa H, et al. Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in non-alcoholic fatty liver disease. Hepatol Res. 2011;41(9):897-903. [PubMed ID: 21682831]. https://doi.org/10.1111/j.1872-034X.2011.00842.x.

  • 21.

    Petta S, Di Marco V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther. 2011;33(12):1350-60. [PubMed ID: 21517924]. https://doi.org/10.1111/j.1365-2036.2011.04668.x.

  • 22.

    Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61(3):409-15. [PubMed ID: 21846782]. https://doi.org/10.1136/gutjnl-2011-300342.

  • 23.

    Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2. [PubMed ID: 22221544]. https://doi.org/10.1186/1471-230X-12-2.

  • 24.

    Blomme B, Francque S, Trepo E, Libbrecht L, Vanderschaeghe D, Verrijken A, et al. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Dig Liver Dis. 2012;44(4):315-22. [PubMed ID: 22119618]. https://doi.org/10.1016/j.dld.2011.10.015.

  • 25.

    Hamman RF, Halil T, Holland WW. Asthma in schoolchildren. Demographic associations and peak expiratory flow rates compared in children with bronchitis. Br J Prev Soc Med. 1975;29(4):228-38. [PubMed ID: 1220834].